Remove 2021 Remove Chemotherapy Remove Communication
article thumbnail

From Trial to Practice in the Evolving Landscape of Hematologic Malignancies

Pharmacy Times

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. Updated August 18, 2021. REFERENCES 1.

article thumbnail

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Pharmacy Times

Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. The primary outcome was the incidence of CR or CRi after induction chemotherapy. Author Disclosures Brian A.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

In 2021, the FDA granted Amgen’s (NASDAQ:AMGN) non-small cell lung cancer (NSCLC) drug Lumakras (sotorasib) an expedited approval, making it the first FDA-approved KRAS inhibitor. In 2021, Amgen agreed to conduct a Phase II study (NCT04933695), which is supposed to complete in May 2024, according to Clinicaltrials.gov.

article thumbnail

Why are my toes numb?

The Checkup by Singlecare

Causes of neuropathy can also include autoimmune diseases like rheumatoid arthritis, nutrient deficiencies, medication toxicity (such as chemotherapy), genetics, and age-related changes, says Dr. Machemehl. Multiple sclerosis is a nervous system disorder that often causes toe numbness.

article thumbnail

SNIPR targets antibiotic resistance with CRISPR-based gene therapy trial

Pharmaceutical Technology

In January 2021, the US Food and Drug Administration (FDA) granted SNIPR001 a fast track designation. Chemotherapy used to treat blood cancer results in increased intestinal permeability, making E. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

article thumbnail

Lymphoma Action – championing the patient voice in cell therapy

pharmaphorum

Now, people living with particular types of lymphoma have individualised options beyond chemotherapy for the first time.”. We’ve learnt how best to communicate with people, their care partners and families, so they’re fully informed and able to take part in the conversation. Last accessed March 2021. Available at: [link].

article thumbnail

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Pharmaceutical Technology

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.